NMS Group is the largest Italian company committed in innovation and research and development in oncology.
With 500 total employees, NMS Group employs over 200 qualified researchers involved in research and development, from 'target validation' to phase II clinical trials.
The discovery and applied research of Nerviano Medical Sciences - representing the innovative heart of the Group and make it an important and international reference in the field of personalized therapy - integrate with other development activities of a new drug. NMS Group is, in fact, the only reality in Italy able to manage the entire integrated chain of the research and development path: from pre-clinical phase of research, to First-Time-In-Man of clinical phase, up to production and packaging of the finished drug.
NMS also provides services of Research and Production addressed to local and international markets through three different companies: Accelera, one of the few companies engaged in preclinical research in Italy; Clioss engaged in clinical development starting from First-Time-In-Man and Nerpharma, dealing with activities from formulation to production of the active principle.
The wide modular structure and the modern technologies of the Center, covering an area of approximately 100 thousand square meters, are structured to offer a range of highly specialized services and additional opportunities of great value to the world of Research and Academy.